热门资讯> 正文
Replimune在黑色素瘤中的RP 1组合结果增加了30%
2024-06-07 00:05
- Replimune Group (NASDAQ:REPL) said that topline results of an analysis of a trial of RP1 plus Bristol-Myers Squibb's (BMY) Opdivo (nivolumab) in melanoma patients who failed on a PD-1 inhibitor indicated one-third of them responded to the combination treatment.
- Patients enrolled in the IGNYTE trial had progressed while on a PD-1 inhibitor for at least 8 weeks.
- Results also showed durability with all responses lasting more than six months and median duration of response of more than 35 months.
- Replimune is up ~30% in early Thursday afternoon trading.
- The company plans to submit a Biologics License Application to the U.S. FDA in the second half of the year and enroll the first patients in the IGNITE-3 confirmatory trial in Q3.
More on Replimune Group
- Replimune: Continuing To Justify The Bear Thesis (For Now)
- Seeking Alpha’s Quant Rating on Replimune Group
- Historical earnings data for Replimune Group
- Financial information for Replimune Group
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
